Kenneth E S Poole
- A single infusion of zoledronate prevents bone loss after strokeKenneth E S Poole
Division of Bone Research, Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, England, UK
Stroke 38:1519-25. 2007..This proof-of-concept study evaluated the efficacy of a single infusion of zoledronate, an intravenous bisphosphonate, in preserving hip bone density after stroke...
- Cortical thickness mapping to identify focal osteoporosis in patients with hip fractureKenneth E S Poole
Department of Medicine, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom
PLoS ONE 7:e38466. 2012..By analysing ordinary clinical CT scans using a novel cortical thickness mapping technique, we discovered patches of markedly thinner bone at fracture-prone regions in the femurs of women with acute hip fracture compared with controls...
- Targeted regeneration of bone in the osteoporotic human femurKenneth E S Poole
Department of Medicine, University of Cambridge, Cambridge, United Kingdom
PLoS ONE 6:e16190. 2011..Applying these methods to the proximal femurs of osteoporotic women, we discover targeted and apparently synergistic effects of pharmaceutical osteoporosis therapy and habitual mechanical load in enhancing bone thickness...
- Bone structure and remodelling in stroke patients: early effects of zoledronateKenneth E S Poole
Division of Bone Research, Department of Medicine, University of Cambridge, Box 157, Addenbrooke s Hospital, Cambridge, England, CB2 2QQ, UK
Bone 44:629-33. 2009..Participants from the trial also volunteered for trans-iliac bone biopsy, to assess the early effects of stroke and zoledronate on iliac bone remodelling...
- Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fractureJon Power
Bone Research Division, Department of Medicine, University of Cambridge, Cambridge, UK
J Bone Miner Res 25:1867-76. 2010..In FNF, full osteonal closure is postponed, with increased porosity, in part because the proportion of osteocytes expressing sclerostin increases sharply with osteonal maturation...
- Rapid long-term bone loss following stroke in a man with osteoporosis and atherosclerosisKenneth E S Poole
MRC Bone Research Group, Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Level 5, Box 157, Cambridge, CB2 2QQ, UK
Osteoporos Int 16:302-5. 2005..There was also an unexpected decline in vertebral BMD after the stroke. This is the first report of the accelerated effect of hemiplegia on bone loss in an already osteoporotic skeleton...
- Changing structure of the femoral neck across the adult female lifespanKenneth E S Poole
Department of Medicine, University of Cambridge, Box 157, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
J Bone Miner Res 25:482-91. 2010..It remains to be determined whether this MDCT technique can provide better prediction of hip fracture than conventional clinical dual X-ray absorptiometry (DXA)...
- Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationKenneth E S Poole
MRC Bone Research Group, Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
FASEB J 19:1842-4. 2005..In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture...
- Reduced vitamin D in acute strokeKenneth E S Poole
Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
Stroke 37:243-5. 2006..Vitamin D deficiency is well documented in long-term stroke survivors and is associated with post-stroke hip fractures. Less is known regarding levels in acute stroke...
- Falls, fractures, and osteoporosis after stroke: time to think about protection?Kenneth E S Poole
Department of Stroke Medicine, Addenbrooke s Hospital, Cambridge, UK
Stroke 33:1432-6. 2002..Stroke patients may also have motor, sensory, and visual/perceptual deficits that predispose them to falls. These factors result in an early but sustained increase in hip fractures after stroke...
- Parathyroid hormone - a bone anabolic and catabolic agentKenneth E S Poole
Division of Bone Research, Department of Medicine, Level 5, University of Cambridge, Addenbrooke s Hospital Box 157, Cambridge CB2 2QQ, UK
Curr Opin Pharmacol 5:612-7. 2005..Microarray analysis has also delineated many genes and pathways regulated by intermittent and continuous PTH in osteoblasts and whole bones...
- Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosisKenneth E S Poole
Department of Medicine, University of Cambridge, Cambridge, UK
J Bone Miner Res 30:46-54. 2015..This mechanism may be involved in the robust decrease in hip fractures observed in denosumab-treated women at increased risk of fracture...
- Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutationsCelia L Gregson
Musculoskeletal Research Unit C L G, J H T, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, United Kingdom Medical Research Council MRC Lifecourse Epidemiology Unit C L G, University of Southampton, Southampton, SO16 6YD United Kingdom Department of Medicine K E S P, University of Cambridge, Cambridge, CB2 0SP United Kingdom Metabolic Bone Centre E V M, Sheffield University, Sheffield, S3 7HF United Kingdom Human Genetics Group E L D, University of Queensland Diamantina Institute, Brisbane, Australia Department of Endocrinology E L D, Royal Brisbane and Women s Hospital, Brisbane, Australia Institute of Aerospace Medicine J R, German Aerospace Center Deutschen Zentrums fuür Luft und Raumfahrt, Cologne, Germany Institute for Biomedical Research into Human Movement and Health Research Institute J R, Manchester Metropolitan University, Manchester, M1 5GD United Kingdom Department of Medicine W D F, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ United Kingdom and MRC Integrative Epidemiology Unit G D S, School of Social and Community Based Medicine, University of Bristol, Bristol, BS8 2BN United Kingdom
J Clin Endocrinol Metab 99:2897-907. 2014..High bone mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown...